Last reviewed 2026-04-19 · How we verify

YPEG-rhEPO

Xiamen Amoytop Biotech Co., Ltd. · Phase 2 active Small molecule

YPEG-rhEPO is a Small molecule drug developed by Xiamen Amoytop Biotech Co., Ltd.. It is currently in Phase 2 development.

At a glance

Generic name	YPEG-rhEPO
Sponsor	Xiamen Amoytop Biotech Co., Ltd.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of YPEG-rhEPO in Patients Suffered From Anemia Due to Chronic Kidney Disease (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

YPEG-rhEPO CI brief — competitive landscape report
YPEG-rhEPO updates RSS · CI watch RSS
Xiamen Amoytop Biotech Co., Ltd. portfolio CI

Frequently asked questions about YPEG-rhEPO

What is YPEG-rhEPO?

YPEG-rhEPO is a Small molecule drug developed by Xiamen Amoytop Biotech Co., Ltd..

Who makes YPEG-rhEPO?

YPEG-rhEPO is developed by Xiamen Amoytop Biotech Co., Ltd. (see full Xiamen Amoytop Biotech Co., Ltd. pipeline at /company/xiamen-amoytop-biotech-co-ltd).

What development phase is YPEG-rhEPO in?

YPEG-rhEPO is in Phase 2.

Manufacturer: Xiamen Amoytop Biotech Co., Ltd. — full pipeline
Compare: YPEG-rhEPO vs similar drugs
Pricing: YPEG-rhEPO cost, discount & access